New York State Teachers Retirement System Increases Stock Position in West Pharmaceutical Services, Inc. $WST

Posted by Brian Himes on Jul 5th, 2026

New York State Teachers Retirement System boosted its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST – Free Report) by 2.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 60,523 shares of the medical instruments supplier’s stock after buying an additional 1,690 shares during the quarter. New York State Teachers Retirement System owned approximately 0.09% of West Pharmaceutical Services worth $15,169,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in WST. Darwin Wealth Management LLC boosted its stake in shares of West Pharmaceutical Services by 10.8% during the 4th quarter. Darwin Wealth Management LLC now owns 410 shares of the medical instruments supplier’s stock worth $113,000 after acquiring an additional 40 shares in the last quarter. IFM Investors Pty Ltd increased its stake in shares of West Pharmaceutical Services by 0.3% in the 1st quarter. IFM Investors Pty Ltd now owns 13,773 shares of the medical instruments supplier’s stock valued at $3,452,000 after purchasing an additional 43 shares in the last quarter. Aptus Capital Advisors LLC raised its holdings in West Pharmaceutical Services by 5.5% in the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock worth $249,000 after purchasing an additional 47 shares during the period. Faithward Advisors LLC raised its holdings in West Pharmaceutical Services by 0.4% in the 3rd quarter. Faithward Advisors LLC now owns 11,855 shares of the medical instruments supplier’s stock worth $3,110,000 after purchasing an additional 48 shares during the period. Finally, PFG Advisors boosted its position in West Pharmaceutical Services by 1.5% during the third quarter. PFG Advisors now owns 3,302 shares of the medical instruments supplier’s stock worth $866,000 after purchasing an additional 50 shares in the last quarter. Hedge funds and other institutional investors own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on the company. KeyCorp raised their price objective on West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a report on Thursday. Barclays raised West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $310.00 to $400.00 in a research note on Tuesday, June 9th. Citigroup reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, April 27th. Finally, Evercore restated an “outperform” rating on shares of West Pharmaceutical Services in a research report on Friday, April 24th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $343.73.

View Our Latest Analysis on West Pharmaceutical Services

West Pharmaceutical Services Price Performance

NYSE:WST opened at $365.87 on Friday. The stock has a 50 day moving average of $322.63 and a two-hundred day moving average of $278.87. West Pharmaceutical Services, Inc. has a 12 month low of $206.80 and a 12 month high of $367.66. The firm has a market cap of $25.85 billion, a P/E ratio of 48.91, a price-to-earnings-growth ratio of 3.06 and a beta of 1.16. The company has a current ratio of 2.71, a quick ratio of 2.04 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST – Get Free Report) last released its earnings results on Thursday, April 23rd. The medical instruments supplier reported $2.13 earnings per share for the quarter, beating the consensus estimate of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to the consensus estimate of $779.67 million. West Pharmaceutical Services had a return on equity of 19.03% and a net margin of 16.85%.The business’s quarterly revenue was up 21.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, analysts expect that West Pharmaceutical Services, Inc. will post 8.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Annette F. Favorite sold 2,817 shares of the company’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president owned 16,828 shares of the company’s stock, valued at $5,135,905.60. This represents a 14.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Chad Winters sold 896 shares of the stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $300.67, for a total transaction of $269,400.32. Following the completion of the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. This trade represents a 37.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Profile

(Free Report)

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.